Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks 1, 2 . Early clinical trials have shown promise, especially in acute myeloid leukaemia 3 , and therefore the evaluation of resistance mechanisms is crucial to optimize the clinical efficacy of these drugs. Here we use primary mouse haematopoietic stem and progenitor cells immortalized with the fusion protein MLL-AF9 to generate several single-cell clones that demonstrate resistance, in vitro and in vivo, to the prototypical BET inhibitor, I-BET. Resistance to I-BET confers cross-resistance to chemically distinct BET inhibitors such as JQ1, as well as resistance to genetic knockdown of BET proteins. Resistance is not mediated through increased drug efflux or metabolism, but is shown to emerge from leukaemia stem cells both ex vivo and in vivo. Chromatin-bound BRD4 is globally reduced in resistant cells, whereas the expression of key target genes such as Myc remains unaltered, highlighting the existence of alternative mechanisms to regulate transcription. We demonstrate that resistance to BET inhibitors, in human and mouse leukaemia cells, is in part a consequence of increased Wnt/b-catenin signalling, and negative regulation of this pathway results in restoration of sensitivity to I-BET in vitro and in vivo. Together, these findings provide new insights into the biology of acute myeloid leukaemia, highlight potential therapeutic limitations of BET inhibitors, and identify strategies that may enhance the clinical utility of these unique targeted therapies.
Bromodomain and extra terminal protein (BET) inhibitors are first-in-class targeted therapies that deliver a new therapeutic opportunity by directly targeting bromodomain proteins that bind acetylated chromatin marks 1, 2 . Early clinical trials have shown promise, especially in acute myeloid leukaemia 3 , and therefore the evaluation of resistance mechanisms is crucial to optimize the clinical efficacy of these drugs. Here we use primary mouse haematopoietic stem and progenitor cells immortalized with the fusion protein MLL-AF9 to generate several single-cell clones that demonstrate resistance, in vitro and in vivo, to the prototypical BET inhibitor, I-BET. Resistance to I-BET confers cross-resistance to chemically distinct BET inhibitors such as JQ1, as well as resistance to genetic knockdown of BET proteins. Resistance is not mediated through increased drug efflux or metabolism, but is shown to emerge from leukaemia stem cells both ex vivo and in vivo. Chromatin-bound BRD4 is globally reduced in resistant cells, whereas the expression of key target genes such as Myc remains unaltered, highlighting the existence of alternative mechanisms to regulate transcription. We demonstrate that resistance to BET inhibitors, in human and mouse leukaemia cells, is in part a consequence of increased Wnt/b-catenin signalling, and negative regulation of this pathway results in restoration of sensitivity to I-BET in vitro and in vivo. Together, these findings provide new insights into the biology of acute myeloid leukaemia, highlight potential therapeutic limitations of BET inhibitors, and identify strategies that may enhance the clinical utility of these unique targeted therapies.
Our increasing knowledge of cancer genomes and epigenomes not only implicates epigenetic regulators in the initiation and maintenance of cancer, but also highlights an opportunity for therapeutic intervention 4, 5 . One of the most promising epigenetic therapies to have f, Resistant clones do not demonstrate cell cycle arrest in biological triplicate experiments (mean 6 s.e.m.). g, Resistance to shRNA-mediated knockdown of Brd4 in biological duplicate experiments (mean 6 s.e.m.). h, i, Kaplan-Meier curve of secondary syngeneic transplant of sensitive (h) and resistant (i) clones (n 5 6 per group, statistical significance calculated using a log-rank test). Dotted line denotes treatment starting on day 9. emerged in the past decade are small molecule inhibitors targeting the bromodomains of BET family proteins (BRD2, BRD3, BRD4 and BRDT) 1, 2 . While these non-catalytic inhibitors are currently being evaluated in clinical trials across a range of malignancies, the molecular and cellular mechanisms that govern sensitivity and resistance remain largely unknown. We and others have previously demonstrated the pre-clinical efficacy of BET inhibitors in acute myeloid leukaemia (AML) [6] [7] [8] , and early clinical evidence has reinforced the potential of these drugs 3 .
To study BET inhibitor resistance in a model of AML, we transduced mouse bone marrow haematopoietic stem and progenitor cells (HSPCs) with MLL-AF9. After a selection period in cytokinesupplemented methylcellulose in the presence of dimethylsulfoxide (DMSO; vehicle) or I-BET at the IC 40 value (40% of maximal inhibitory effect concentration) of these cells (400 nM), we isolated individual blast colonies, each derived from a single cell, to generate four independent vehicle-treated and five independent I-BET-resistant cell lines (Fig. 1a) . The selection pressure on I-BET-resistant clones was sequentially increased to establish clones stably growing at various concentrations including those greater than the IC 90 value of the parental and vehicle-treated cells (Fig. 1a, b and Extended Data Fig. 1a ). While chemically distinct inhibitors directed against the same target have sometimes overcome resistance 9 , our data indicates that resistance to I-BET also confers cross-resistance to the chemically distinct BET inhibitor JQ1 (ref. 10) (Fig. 1c and Extended Data Fig. 1b) .
Direct comparison of these cell lines demonstrated that although vehicle-treated cells remained exquisitely sensitive to I-BET-mediated suppression of clonogenic capacity, induction of apoptosis and cell cycle arrest, the resistant cells were now impervious to these established phenotypic responses at levels that positively correlated with the degree of selective pressure applied (Fig. 1d-f and Extended Data Fig.  1c ). High-content short hairpin RNA (shRNA) screens in this AML model previously identified Brd4 as the major therapeutic target of BET inhibitors 8 . Using an inducible shRNA system, we were able to replicate these findings in our vehicle-treated clones; however, BETinhibitor-resistant clones were significantly less susceptible to genetic depletion of Brd4 ( Fig. 1g and Extended Data Fig. 1d-h) .
Consistent with our previous data 7 , I-BET leads to a significant survival advantage in this AML model (Fig. 1h) . By contrast, this survival advantage is abrogated following an identical treatment strategy in recipients of resistant cells (Fig. 1i) . No differences in morphology or pattern of disease between sensitive or resistant cells were observed (Extended Data Fig. 1i and data not shown). Together, these findings establish a robust model of BET inhibitor resistance in vitro 
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1 populations in resistant clones performed in biological duplicate (mean 6 s.e.m.). d, Limiting dilution transplantation analyses Kaplan-Meier curves of C57BL/6 mice injected with indicated number of cells; detailed cohort and survival data can be found in Extended Data Fig. 3a . e, LSC frequency from limiting dilution transplantation analyses. Dotted lines indicate 95% confidence intervals (CI). f, L-GMP frequency in whole mouse bone marrow (mean 6 s.e.m.) after serial transplantation of I-BET-exposed leukaemias from in vivo resistance model. Statistical significance of survival outcomes determined using log-rank test of Kaplan-Meier survival estimates. g, Proportion of human leukaemic CD34 1 cells, GMPs and LMPPs in whole mouse bone marrow (mean 6 s.e.m.) after I-BET exposure in an AML PDX model (n 5 5). h, I-BET-naive L-GMPs do not demonstrate intrinsic resistance to I-BET in clonogenic assays in biological duplicate experiments (mean 6 s.e.m.), see also Extended Data Fig. 5b . M1, mouse 1. 
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and in vivo, and show that resistant cells are refractory to either chemical or genetic perturbation of Brd4.
Major mechanisms of drug resistance include reduced drug influx or increased drug efflux 11 . To address this issue, we performed quantitative mass spectrometry, which revealed no significant difference in the amount of intracellular or extracellular drug (Fig. 2a) . However, we noted that resistant cells were smaller and more homogenous by flow cytometry (Extended Data Fig. 1j) , and further immunophenotypic characterization of sensitive and resistant cells revealed marked differences in the expression of the lineage markers Gr1 and CD11b (Fig. 2b) . These findings were replicated in an independent MLL-ENL model of BET inhibitor resistance (Extended Data Fig. 2) .
While the precise immunophenotype of leukaemia stem cells (LSCs) in mouse MLL leukaemia models has been debated [12] [13] [14] , it has previously been shown that LSC potential primarily resides in the more immature, lineage-negative (Lin 12, 14, 15 . Consistent with this notion, we noted a significant increase in the blast colony forming potential of the Lin 2 (Gr1
2
/CD11b
2 ) population, and a marked increase in L-GMP cells in our resistant population before primary transplantation (Fig. 2c and Extended Data Fig. 1k ).
While primary transplantation of vehicle-treated cells paralleled the natural history of this AML model, remarkably, primary transplantation of I-BET-resistant cells resulted in considerably shorter leukaemia latency (Fig. 2d) . Moreover, limiting dilution transplantation analyses confirm that I-BET-resistant cells were markedly enriched for LSC potential (Fig. 2d, e and Extended Data Fig. 3a) . To assess the relevance of these findings to resistance that emerges in vivo after sustained exposure to I-BET, we derived an independent in vivo model of I-BET resistance (Extended Data Fig. 3b, c) . These data validated findings from the ex vivo model, and show that in vivo BET-inhibitor resistance also emerges from an L-GMP/LSC population ( Fig. 2f and Extended Data Fig. 3d-g ). Importantly, these I-BET-resistant AML cells have a functional LSC frequency of approximately 1:6; this is virtually identical to what has previously been reported for a purified L-GMP population 12 .
To extend these findings into primary patient samples we treated a patient-derived xenograft (PDX) model of AML with I-BET. While the immunophenotype of human AML LSCs can be variable 16 , several PDX models have shown that LSCs are enriched within CD34 RESEARCH LETTER cells 16, 17 , which immunophenotypically parallel GMPs or lymphoidprimed multipotent progenitors (LMPPs) 18 . Consistent with the data from our mouse AML models, we find that I-BET treatment enriches for the leukaemic LMPP population (Fig. 2g and Extended Data Fig. 4) .
To understand whether LSCs were intrinsically resistant to I-BET, we sorted L-GMPs from mice that were I-BET-naive, and challenged them with 1 mM of I-BET in clonogenic assays. While this dose virtually eradicates the clonogenic potential of I-BET-naive bulk leukaemia cells (Fig. 1d and ref. 7) , between 30 and 40% of L-GMPs are able to survive (Fig. 2h and Extended Data Fig. 5 ). Moreover, initial treatment with I-BET in vivo does not result in an immediate increase in L-GMPs, instead this population progressively emerges with continuous and sustained exposure to drug in vivo (Fig. 2f) . These findings suggest that immunophenotypically homogenous L-GMPs/LSCs show marked heterogeneity in their response to I-BET, and that not all L-GMPs are intrinsically resistant to BET inhibitors.
We next sought to understand whether BET inhibitor resistance was reversible in the absence of continuing selective pressure with I-BET. Surprisingly we find that BET inhibitor sensitivity was only partially restored ( Fig. 3a, b) , and these cells only partially reacquire the immunophenotype of sensitive I-BET-naive cells (Fig. 3c) . Moreover, transcriptionally, they also adopt an intermediate state between sensitive cells and those resistant to I-BET above the IC 60 value of the drug (Fig. 3g) .
To explore the molecular aetiology for BET inhibitor resistance further, we initially performed whole-exome sequencing in the parental and two separate vehicle/I-BET-resistant cell lines ( Fig. 3d and Extended Data Fig. 6 ). Similar to human leukaemias driven by MLL fusion proteins 19 , these mouse leukaemia cells do not demonstrate significant genomic instability (Extended Data Fig. 6 ). Notably, although independently established resistant clones behaved identically in all functional analyses described above, there were no gatekeeper mutations in the bromodomains of Brd2/3/4, and no shared copy number aberrations. Moreover, only a few mutations with no apparent functional relevance to AML and/or BET activity were shared across several resistant cell lines (Fig. 3d and Extended Data Fig. 6a, b) .
We, and others, have shown that treatment with BET inhibitors results in incomplete displacement of Brd2, Brd3 and Brd4 from chromatin 6, 20 . Similarly, we noticed that resistant cells stably growing in I-BET also showed a decrease in chromatin-bound Brd2, Brd3 and Brd4 ( Fig. 3e and Extended Data Fig. 7a, b) . Notably, however, we found that key Brd4 target genes such as Myc were equally expressed in resistant cells despite loss of Brd4 from functional Myc enhancer elements (Figs 3f and 4g ). These findings raised the prospect that alternative compensatory transcriptional programmes were active in BET-resistant cells.
Global transcriptome analyses using two distinct methodologies showed a very high degree of correlation, and highlighted several transcriptional changes that clearly distinguished sensitive from resistant cells ( Fig. 3g and Extended Data Fig. 7c, d) . Notably, and consistent with our functional data, gene set enrichment analyses (GSEA) of our resistant cells strongly overlapped with previously published transcriptome data of LSCs from this AML model 12, 15 ( Fig. 3h and Extended Data Fig. 7e-j) . To identify precise transcriptional programmes differentially expressed, we performed GSEA for major signalling pathways. These findings demonstrated that the NF-kB pathway was significantly downregulated, whereas both the TGF-b and Wnt/b-catenin pathways were significantly upregulated in our resistant cells (Fig. 3i) .
We focused our attention on the Wnt/b-catenin pathway as several components from ligand receptors to transcriptional co-activators were noted to be transcriptionally upregulated (Extended Data  Fig. 8a ). Interestingly, this pathway has previously been shown to be a major protagonist involved in sustaining LSCs in these models of AML 14, 21 and in other cancer stem cells 22 (Extended Data Fig. 8b ). To antagonise Wnt/b-catenin signalling specifically, we overexpressed the Dickkopf Wnt signalling pathway inhibitor 1 (Dkk1), which resulted in the differentiation of our resistant cells into more mature leukaemic blasts ( Fig. 4a and Extended Data Fig. 8f ) and re-instated sensitivity to I-BET both in vitro and in vivo ( Fig. 4b and Extended Data Fig. 8c-h ). In support of these findings, pyrvinium, an established inhibitor of the Wnt/b-catenin pathway 23 , phenocopied these results ( Mechanistically, we find that in I-BET-naive cells, Brd4 is bound to the cis-regulatory elements of target genes such as Myc (Fig. 3f) , whereas b-catenin is essentially absent (Fig. 4f) . However, in I-BET-resistant cells, Brd4 binding is decreased (Fig. 3f ), but b-catenin is now bound at these sites and able to sustain the expression of Myc (Fig. 4f, g ). Negative regulation with Dkk1 reduces chromatin-bound b-catenin and subverts its ability to maintain the expression of Myc (Fig. 4f , g and Extended Data Fig. 8h ). Analogous to the events at Myc, we find that in the resistant cells, chromatin occupancy of b-catenin increases at the sites where Brd4 is displaced from chromatin, and this increased b-catenin occupancy is abrogated by the expression of Dkk1 (Fig. 4h) .
We have previously shown that BET inhibitors have a broad range of efficacy against human AML samples 6, 7 . To explore the translational relevance of our findings, we compared baseline expression of WNT/ b-catenin target genes to the degree of I-BET-induced apoptosis in these samples (Extended Data Fig. 10a ). Notably, we find a high degree of correlation ( Fig. 4i and Extended Data Fig. 10 ), supporting our findings that increased activity of the WNT/b-catenin pathway negates the effects of BET inhibition.
New classes of anti-cancer therapy rarely emerge, and BET inhibitors have uncovered a new therapeutic precedent; the possibility of specifically targeting epigenetic readers (effector proteins that recognize specific epigenetic modifications on histones or nucleotides). If their early clinical promise is to be realized, it is imperative that we evaluate their limitations and mechanisms of resistance to identify rational strategies that enhance their efficacy. Using models that have recapitulated the hierarchical structure of AML in vitro and in vivo, we show that BET inhibitor resistance emerges from LSCs with increased expression of the Wnt/b-catenin pathway. While not all LSCs are intrinsically resistant, it is clear that a small proportion of these are either transcriptionally primed or display rapid transcriptional plasticity to survive the initial BET inhibitor challenge, these cells subsequently thrive and become the dominant population (Fig. 4j ). This adaptive transcriptional plasticity is an emerging theme by which malignant cells are able to escape from therapeutic pressures 24 , and our findings are consistent with another report highlighting the WNT/b-catenin pathway as a mechanism to circumvent BET inhibition 25 . Our approach has allowed us to sustain a highly enriched population of LSCs in culture indefinitely, providing a unique resource to characterize LSCs molecularly and enable screening of a range of therapies that may ultimately deliver the opportunity to eradicate the LSC population.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Generation of immortalized primary mouse HSPC lines and derivation of clonal cell lines. Initial generation of immortalized parental cell lines was achieved through magnetic bead selection (Miltenyi Biotec) of c-kit positive cells, obtained from whole bone marrow of male and female C57BL/6 mice, and subsequent retroviral transduction with either an MSCV-MLL-AF9-IRES-YFP or an MSCV-MLL-ENL construct.
To generate clonal resistant cell lines, the MLL-AF9-bearing parental cell line was serially re-plated in cytokine-supplemented methylcellulose (Methocult M3434, StemCell Technologies) containing either vehicle (0.1% DMSO) or drug (400 nM I-BET151). Individual vehicle-treated or resistant colonies were picked and transferred to liquid culture to generate clonal cell lines. Resistant cell lines were maintained continuously in drug while being incrementally exposed to increasing concentrations of drug (up to 1 mM I-BET151). Vehicle treated clones were also continuously maintained in 0.1% DMSO and passaged in identical fashion. The parental cell line was continuously maintained with no exposure to vehicle or drug.
Similarly, to generate resistant cell lines, the MLL-ENL-bearing parental cell line was serially re-plated in cytokine-supplemented methylcellulose containing either vehicle (0.1% DMSO) or drug (400 nM I-BET151). Cells growing in each plate were then washed and transferred to liquid culture to generate cell lines. Resistant cell lines were maintained continuously in drug while being incrementally exposed to increasing concentrations of drug (up to 1 mM I-BET151). Vehicle-treated clones were also continuously maintained in 0.1% DMSO and passaged in identical fashion. The parental cell line was continuously maintained with no exposure to vehicle or drug. Cell culture. Primary mouse haematopoietic progenitors and derived cell lines were grown in RPMI-1640 supplemented with mouse IL-3 (10 ng ml 21 ), 20% FCS, penicillin (100 U ml ) and SCF (50 ng ml 21 ). Cells were incubated at 37uC and 5% CO 2 . Cell proliferation assays. For dose-response assays, serial dilutions of I-BET151, JQ1 or pyrvinium were further diluted in media before addition to 96-well plates seeded with between 5 3 10 3 and 1 3 10 4 cells per well to obtain a 0.1% DMSO final concentration. After 72 h incubation, resazurin was added to each well and plates were further incubated for 3 h. Fluorescence was then read at 560 nm/590 nm on a Cytation 3 Imaging Reader (BioTek). Cell counts were performed using a haemocytometer. Determination of in vitro synergy in proliferation assays was undertaken according to the method described previously 26 . Clonogenic assays in methylcellulose. Clonogenic potential was assessed through colony growth of derived cell lines plated in cytokine-supplemented methylcellulose (Methocult M3434, StemCell Technologies). Derived vehicletreated and resistant cell lines were plated in duplicate at a cell dose of 2 3 10 2 per plate in the presence of vehicle (0.1% DMSO) or drug (1 mM I-BET151). Gr1
2
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2 and Gr1 1 /CD11b 1 fractions of resistant cell lines were plated in duplicate following FACS sorting at a cell dose of between 2 3 10 2 and 2 3 10 3 cells per plate. FACS-isolated L-GMP populations from whole mouse bone marrow following primary syngeneic transplant of vehicle-treated clones were plated in duplicate at a cell dose of between 2 3 10 2 and 2 3 10 3 cells per plate in the presence of vehicle (0.1% DMSO) or drug (1 mM I-BET151). Cells were incubated at 37 uC and 5% CO 2 for 7-10 days at which time colonies were counted. Flow cytometric analyses. Cell apoptosis was assessed using APC conjugated Annexin V (550475, BD Biosciences) and propidium iodide (PI) (P4864, Sigma-Aldrich) staining according to manufacturer's instructions.
For cell cycle analysis, cells were fixed overnight at 220 uC in 70% ethanol/PBS. Before flow cytometry analysis, cells were incubated at 37 uC for 30 min in PI staining solution (0.02 mg ml 21 PI, 0.05% (v/v) Triton X-100 in PBS, supplemented with DNase-free RNase A (19101, Qiagen)) or incubated at room temperature for 10 min with 49,6-diamidino-2-phenylindole (DAPI) staining solution (1 mg ml 21 DAPI, 0.05% (v/v) Triton X-100 in PBS). Immunophenotype assessment for markers of committed differentiation was undertaken through staining with Alexa Fluor 700 anti-Gr1 (108422, BioLegend) and Brilliant Violet 605 anti-CD11b (101237, BioLegend). Assessment of L-GMP populations was undertaken through staining with eFluor 660 anti-CD34 (50-0341-82, eBioscience), biotin lineage antibody cocktail (120-001-547, Miltenyi Biotec), PerCP/Cy5.5 anti-CD16/32 (101324, BioLegend), APC/Cy7 anti-CD117 (105826, BioLegend) and Pacific Blue anti-Ly-6A (122520, BioLegend) followed by secondary staining with V500 streptavidin (561419, BD Biosciences). Assessment of leukaemic LMPP and GMP populations in patient-derived xenografts was undertaken through staining with APC/Cy7 anti-mouse CD45.1 (110716, Biolegend), eFluor 450 anti-mouse Ter119 (48-5921-82, eBioscience), FITC anti-human CD45 (11-9459-42, eBioscience), BV711 anti-human CD38 (563965, BD Biosciences), PE anti-human CD90 (561970, BD Biosciences), PE-Cy5 anti-human CD123 (15-1239-41, eBioscience), PerCP-Cy5.5 anti-human CD45RA (45-0458-42), biotin anti-human CD3 (555338, BD Biosciences), biotin anti-human CD19 (555411, BD Biosciences), PE-Cy7 anti-human CD33 (333946, BD Biosciences) and APC anti-human CD34 (555824, BD Biosciences) followed by secondary staining with V500 streptavidin (561419, BD Biosciences).
PI or DAPI was used as a viability dye to ensure that immunophenotyping analyses were performed on viable cells. Appropriate unstained, single-stained and fluorescence minus one controls were used to determine background staining and compensation in each channel.
Flow cytometry analyses were performed on a LSRFortessa X-20 flow cytometer (BD Biosciences) and all data analysed with FlowJo software (vX.0.7, Tree Star). Cell sorting was performed on a FACSAria Fusion flow sorter (BD Biosciences). RNA interference studies. shRNAs were cloned into TtRMPVIR (27995, addgene). For competitive proliferation assays, transduced cells were sorted for shRNA-containing (Venus The following shRNA sequences were used: Brd2 (#851), 59-CGGATTATCA CAAAATTAT-39; Brd4 (#498), 59-ACTATGTTTACAAATTGTT-39; Brd3/4 (#499), 59-AGGACTTCAACACTATGTT-39; Brd4 (#500), 59-AGCAGAACAA ACCAAAGAA-39.
shRNAs directed against Apc were cloned into LMN-mirE-mCherry. The proportion of shRNA-expressing (mCherry qRT-PCR. mRNA was prepared using the Qiagen RNeasy kit and cDNA synthesis was performed using SuperScript VILO kit (Life Technologies) as per manufacturer's instructions. qPCR analysis was undertaken on an Applied Biosystems StepOnePlus System with SYBR green reagents (Life Technologies).
For analysis of mouse cell line samples, expression levels were determined using the DC T method and normalized to b-2-microglobulin (B2m) and/or Gapdh. Differences in expression were assessed using a one-sided t-test for statistical significance. Assessment of expression changes associated with I-BET151 treatment occurred at 6 h after treatment with 1 mM I-BET151.
The following mouse primer pairs were used: Apc, forward 59-GGAGTGGC AGAAAGCAACAC-39, reverse 59-AAACACTGGCTGTTTCGTGA-39; B2m, forward 59-GAGCCCAAGACCGTCTACTG-39, reverse 59-GCTATTTCTTTC TGCGTGCAT-39; Brd2, forward 59-TGGGCTGCCTCAGAATGTAT-39, reverse 59-CCAGTGTCTGTGCCATTAGG-39; Brd3, forward 59-GCCAGTGAGTGTA TGCAGGA-39, reverse 59-GCCTGGGCCATTAGCACTAT-39; Brd4, forward 59-TCTGCACGACTACTGTGACA-39, reverse 59-GGCATCTCTGTACTCTC GGG-39; Ccnd2, forward 59-CAAGCCACCACCCCTACA-39, reverse 59-TTGC CGCCCGAATGG-39; Dkk1, forward 59-CTGCATGAGGCACGCTATGT-39, reverse 59-AGGAAAATGGCTGTGGTCAG-39; Dvl1, forward 59-ATCACAC GCACCAGCTCTTC-39, reverse 59-GGACAATGGCACTCATGTCA-39; Fzd5, forward 59-GGCTACAACCTGACGCACAT-39, reverse 59-CAGAATTGGTG CACCTCCAG-39; Gapdh, forward 59-GGTGCTGAGTATGTCGTGGA-39, reverse 59-CGGAGATGATGACCCTTTTG-39; Gsk3b, forward 59-TTGGAGC CACTGATTACACG-39, reverse 59-CCAACTGATCCACACCACTG-39; Myc, forward 59-TGAGCCCCTAGTGCTGCAT-39, reverse 59-AGCCCGACTCCGA CCTCTT-39.
For determination of baseline WNT/b-catenin pathway and target gene expression in primary human AML samples, expression relative to the mean of all samples was determined using the DC T method and normalized to GAPDH and actin. The following human primers were used: AXIN2, forward 59-CGGA CAGCAGTGTAGATGGA-39, reverse 59-CTTCACACTGCGATGCATTT-39; CCND1, forward 59-GCTGTGCATCTACACCGACA-39, reverse 59-CCACTT GAGCTTGTTCACCA-39; CTNNB1, forward 59-GACCACAAGCAGAGTGC TGA-39, reverse 59-CTTGCATTCCACCAGCTTCT-39; FZD5, forward 59-TTC CTGTCAGCCTGCTACCT-39, reverse 59-CGTAGTGGATGTGGTTGTGC-39; MYC, forward 59-CTGGTGCTCCATGAGGAGA-39, reverse 59-CCTGCCTC TTTTCCACAGAA-39; TCF4, 59-ATGGCAAATAGAGGAAGCGG-39, reverse 59-TGGAGAATAGATCGAAGCAAG-39; ACTB, forward 59-TTCAACACCC
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CAGCCATGT-39, reverse 59-GCCAGTGGTACGGCCAGA-39; GAPDH, 59-AC GGGAAGCTTGTCATCAAT-39, reverse 59-TGGACTCCACGACGTACTCA-39.
Immunoblotting. Whole-cell lysates were mixed with Laemmli SDS sample buffer, separated via SDS-PAGE and transferred to PVDF membranes (Millipore). Membranes were then sequentially incubated with primary antibodies (see antibodies) and secondary antibodies conjugated with horseradish peroxidase (Invitrogen). Membranes were then incubated with ECL (GE Healthcare) and proteins detected by exposure to X-ray film. Mouse tissue sample preparation. Peripheral blood samples were collected in EDTA-treated tubes (Sarstedt) and counted using a XP-100 analyser (Sysmex). Single-cell cytospins and blood smears were stained with the Rapid Romanowsky Staining Kit (Thermo Fisher Scientific). Bone marrow cells were isolated by flushing both femurs and tibias with cold PBS. Before flow cytometry, red blood cells were lysed in red blood cell lysis buffer (Sigma). Examination of drug efflux and metabolism by quantitative mass spectrometry. Between 2 3 10 5 and 3 3 10 5 cells per well were seeded in 24-well plates and treated with vehicle (0.1% DMSO) or 600 nM I-BET151. After 48 h, cells were collected by centrifugation, washed twice in ice-cold PBS and lysed in M-PER buffer (78501, Thermo Scientific). Base media, supernatant, wash and cell lysates were quenched with 5% acetonitrile (aq) containing labetalol at 62.5 ng ml 21 as the internal standard. These samples, in addition to serial dilutions of I-BET151 used to generate standard curves, were then analysed by mass spectrometry.
HPLC-mass spectrometry apparatus and conditions: The HPLC system was an integrated CTC PAL auto sampler (LEAP technologies), Jasco XTC pumps (Jasco). The HPLC analytical column was an ACE 2 C18 30 mm 3 2.1 mm (Advanced Chromatography Technologies) maintained at 40 uC. The mobile phase solvents were water containing 0.1% formic acid and acetonitrile containing 0.1% formic acid. A gradient ran from 5% to 95% ACN plus 0.1% formic acid up to 1.3 min, held for 0.1 min and returning to the starting conditions over 0.05 min then held to 1.5 min at a flow rate of 1 ml min 21 . A divert valve was used so the first 0.4 min and final 0.2 min of flow were diverted to waste.
Mass spectromic detection was by an API 4000 triple quadrupole instrument (AB Sciex) using multiple reaction monitoring (MRM). Ions were generated in positive ionization mode using an electrospray interface. The ionspray voltage was set at 4,000 V and the source temperature was set at 600uC. For collision dissociation, nitrogen was used as the collision gas. The MRM of the mass transitions for I-BET151 (m/z 416.17 to 311.10), and labetalol (m/z 329.19 to 162.00), were used for data acquisition.
Data were collected and analysed using Analyst 1.4.2 (AB Sciex), for quantification, area ratios (between analyte/internal standard) were used to construct a standard line, using weighted (1/x 2 ) linear least squared regression, and results extrapolated the area ratio of samples from this standard line. Mouse models of leukaemia. Primary syngeneic transplantation studies of stably growing derived vehicle treated or resistant cell lines in limit dilution analyses were performed with intravenous injection of between 1 3 10 1 to 2 3 10 6 cells per mouse. Serial syngeneic transplantation studies of drug efficacy, generation of in vivo resistance and limit dilution analyses were performed with intravenous injection of between 1 3 10 1 to 2.5 3 10 6 cells per mouse obtained from bone marrow or spleen. Treatment with vehicle or I-BET151 at 20-30 mg kg 21 began between days 9 and 13. Pyrvinium, alone or in combination with I-BET151, was delivered between days 9 and 26.
After stable retroviral transduction of resistant cell lines with a Dkk1 containing construct, 5 3 10 6 cells per mouse were injected intravenously in primary syngeneic transplants. Treatment with vehicle or I-BET151 at 20 mg kg 21 began at day 16.
Syngeneic transplantation studies were performed in C57BL/6 mice (wild-type or expressing Ptprc a ). All mice were 6-10 weeks old at the time of sub-lethal irradiation (300 cGy) and intravenous cell injection. Treatment with vehicle, I-BET151 or pyrvinium commenced after engraftment of leukaemia as determined by .1% yellow fluorescent protein (YFP) expression in peripheral blood in most mice. Mice were randomly assigned treatment groups; treatment administration was not blinded. Sample sizes were determined according to the resource equation method. Differences in Kaplan-Meier survival curves were analysed using the log-rank statistic.
Patient derived xenograft studies were performed in NOD/SCID/Il2rg 2/2 (NSG) mice. All mice were 6-10 weeks old at the time of sub-lethal irradiation (200 cGy) and intravenous cell injection of 1 3 10 5 to 5 3 10 5 cells per mouse. Treatment with vehicle or I-BET151 at 10 mg kg 21 for a 2-week period began after detection of .1% circulating human CD45 1 cells in mouse peripheral blood at week 14. Treatment cohorts were matched for transplant generation.
I-BET151 was dissolved in normal saline containing 5% (v/v) DMSO and 10% (w/v) Kleptose HPB. I-BET151 was delivered daily (5 days on, 2 days off) by intraperitoneal injection (10 ml kg 21 ) with dose reduction of I-BET151 undertaken if evidence of drug intolerance was present. Pyrvinium was dissolved in normal saline containing 15% (v/v) DMSO and delivered daily by intraperitoneal injection (10 ml kg 21 ). Dosing of pyrvinium started at 0.1 mg kg 21 and escalated in 0.1 mg kg 21 increments every second dose to a maximal dose of 0.5 mg kg
21
. All mice were kept in a pathogen-free animal facility, inspected daily and euthanized on signs of distress/disease. All experiments were conducted under either UK Home Office regulations or Institutional Animal Ethics Review Board in Australia. Statistical analyses of limit dilutions were undertaken according to the method described previously 27 . Exome capture sequencing. DNA was extracted from cell lines using the DNeasy blood and tissue kit (Qiagen), and quantified using the Qubit dsDNA HS Assay (Life Technologies) before fragmentation to a peak size of approximately 200 base pairs (bp) using the focal acoustic device, SonoLab S2 (Covaris). Library preparations were performed using the SureSelect XT Target Enrichment System for Illumina Paired-End Sequencing Library protocol (Agilent Technologies) with the SureSelect XT Mouse All Exon Kit for the capture process (Agilent Technologies). The quality of libraries submitted for sequencing was assessed using the High Sensitivity DNA assay on the 2100 bioanalyzer (Agilent Technologies). Libraries were quantified with qPCR, normalized and pooled to 2 nM before sequencing with paired end 100-bp reads using standard protocols on the HiSeq2500 (Illumina).
The Fastq files generated by sequencing were aligned to the mm10 mouse reference genome using bwa 28 . Copy number variation was analysed using ADTEx 29 33 was used to predict the functional effect of the identified variants. Mutations detected by at least two variant callers were further analysed for shared mutations between cell lines and mutation spectrum. Genomic regions with coverage of at least eight reads in all libraries were analysed for the frequency of mutations. Coding exonic, untranslated regions and intronic regions were obtained from the UCSC Table Browser   34 . Upstream regions were defined as 1,000 bp upstream of genes, downstream regions were defined as 1,000 bp downstream of genes, and intergenic regions were more than 1,000 bp from genes. ChIP, qPCR and sequencing analysis. Cells were cross-linked with 1% formaldehyde for 15 min at room temperature and cross-linking stopped by the addition of 0.125 M glycine. Cells were then lysed in 1% SDS, 10 mM EDTA, 50 mM Tris-HCl, pH 8.0, and protease inhibitors. Lysates were sonicated in a Covaris ultrasonicator to achieve a mean DNA fragment size of 500 bp. Immunoprecipitation (see antibodies) was performed for a minimum of 12 h at 4uC in modified RIPA buffer (1% Triton X-100, 0.1% deoxycholate, 90 mM NaCl, 10 mM Tris-HCl, pH 8.0 and protease inhibitors). An equal volume of protein A and G magnetic beads (Life Technologies) were used to bind the antibody and associated chromatin. Reverse crosslinking of DNA was followed by DNA purification using QIAquick PCR purification kits (Qiagen). Immunoprecipitated DNA was analysed on an Applied Biosystems StepOnePlus System with SYBR green reagents. The following primer pairs were used in the analysis: Myc TSS, forward 59-GTC ACCTTTACCCCGACTCA-39, reverse 59-TCCAGGCACATCTCAGTTTG-39; Myc enhancer, forward 59-TCTTTGATGGGCTCAATGGT-39, reverse 59-TTC CCTTCACCTGATGAACC-39. For sequencing analysis of immunoprecipitated DNA, DNA was quantified using the Qubit dsDNA HS Assay (Life Technologies). Library preparations were performed using the standard ThruPLEXTM-FD Prep Kit protocol (Rubicon Genomics) and size selected for 200-400 bp using the Pippen Prep (Sage Science Inc.). Fragment sizes were established using either the High Sensitivity DNA assay or the DNA 1000 kit and 2100 bioanalyzer (Agilent Technologies). Libraries were quantified with qPCR, normalized and pooled to 2 nM before sequencing with single-end 50-bp reads using standard protocols on the HiSeq2500 (Illumina). The Fastq files generated by sequencing were aligned to the mm10 mouse reference genome using bwa 28 . Peak-calling was performed using MACS2 (ref. 35 ) with default parameters and the input library as control. Profiles and heat maps of reads and MACS peaks in the 5 kb around the TSS were generated with Genomic Tools 36 . Expression analysis by microarray and RNA-sequencing. RNA was prepared using the Qiagen RNeasy kit. For microarray analysis, RNA was hybridized to Illumina MouseWG-6 v2 Expression BeadChips. Gene expression data were processed using the lumi package in R. Probe sets were filtered to remove those where the detection P value (representing the probability that the expression is above the background of the negative control probe) was greater than 0.05 in at least one sample. Expression data was background corrected and quantile normalized. Normalization and inference of differential expression were performed using limma 37 . Correction for multiple testing was performed using the method of Benjamini and Hochberg 38 . Genes with an FDR rate below 0.05 and a fold-change greater than 2 were considered significantly differentially expressed. For genes
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with multiple probe sets, only the probe set with the highest average expression across samples was used.
For RNA sequencing analysis, RNA concentration was quantified with the NanoDrop spectrophotometer (Thermo Scientific). The integrity was established using the RNA 6000 kit and 2100 bioanalyzer (Agilent Technologies). Library preparations were performed using the standard TruSeq RNA Sample Preparation protocol (Illumina) with fragment sizes established using the DNA 1000 kit and 2100 bioanalyzer (Agilent Technologies). Libraries were quantified with qPCR, normalized and pooled to 2 nM before sequencing with paired-end 50 bp reads using standard protocols on an Illumina HiSeq2500.
Reads were aligned to the mouse genome (Ensembl Release 75, Feb 2014) using Subread 39 and assigned to genes using featureCounts 40 . Differential expression was inferred using limma/voom 37 . Correction for multiple testing using the Benjamini-Hochberg method was performed. Genes with an FDR below 0.05 and a fold-change greater than 2 were considered significantly differentially expressed.
Gene set enrichments were determined using ROAST 41 . ROAST tests for up-or downregulation of genes in a given pathway (Fig. 3i) were performed on cell lines either stably maintained in vehicle or I-BET. P values were corrected for multiple testing using the method of Benjamini and Hochberg. Gene sets were obtained from MSigDB 42 and curated. Human Entrez accessions from the downloaded gene sets were converted into mouse accessions using orthologue information from the Mouse Genome Database (MGD) at the Mouse Genome Informatics website (http://www.informatics.jax.org; accessed June 2014). ROAST tests were performed to assess for an enrichment of a LGMP gene expression signature (GSE4416) 12 and a LGMP derived from HSC signature (GSE18483) 15 Correlation of log gene expression of selected WNT/b-catenin pathway genes was assessed using a corrgram and correlation between log expression and apoptosis was examined using scatterplots. As expression between genes was typically highly correlated, or inversely correlated, the log-expression data was summarized using the first principle component and compared to the level of apoptosis. A multiple linear regression model was also fitted to the data. As the full model was close to saturated (8 samples, 6 genes), a stepwise model selection procedure based on the Akaike Information Criteria (AIC), which was implemented in the R function STEP, was used. The model that minimized the AIC excluded one gene (AXIN2). Patient material. Peripheral blood or bone marrow containing .80% blasts was obtained from patients following consent and under full ethical approval at each involved institute. I-BET naive n 5 6, I-BET exposed n 5 6. Third transplant: I-BET naive n 5 2, I-BET exposed n 5 3. Fourth transplant: I-BET naive n 5 2, I-BET exposed n 5 3. Fifth transplant: I-BET naive n 5 4, I-BET exposed n 5 5. d, Limit dilution analyses of leukaemias derived from bone marrow of diseased mice chronically exposed to I-BET after the fourth transplant demonstrates that less than 10 cells are reliably able to transfer leukaemia. Kaplan-Meier curves of C57BL/6 mice injected with indicated number of cells. e, Chronic I-BET exposure significantly enriches for leukaemia stem cells in vivo. f, Transplant cohorts and survival of limit dilution analyses of data displayed in d and e. g, Gating strategy for identification of L-GMPs in whole mouse bone marrow. 
23
. i, RNA-seq identifies enrichment of LSC gene expression signature following chronic in vivo BET inhibitor exposure. Heat map of differential mRNA expression data from RNA-seq of leukaemias from the bone marrow of I-BET-exposed (n 5 2) and I-BET-naive (n 5 2) mice after the fourth transplant. j, GSEA of RNA-seq data identifies enrichment of a previously published LSC gene expression signature in leukaemias chronically exposed to I-BET in vivo. Barcode plot compares differential expression of genes in I-BET-exposed and I-BET-naive leukaemias to published data comparing L-GMPs and MLL-AF9 cells propagated in liquid culture. Shaded area in the centre of plot shows genes ranked by fold change in expression in I-BET-exposed relative to I-BETnaive leukaemias. Pink and blue shading represent significantly up-and downregulated genes, respectively. Upregulated and downregulated genes in the previously published LSC gene expression signature are shown in red and blue, respectively, and correlate with expression of genes in the I-BETexposed leukaemias (FDR 5 0.05). RESEARCH LETTER
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